The creator expresses concerns about Hims & Hers Health's business model, prescription process, and premium pricing, leading to a decision to avoid the stock.
Source Post
Hims Earnings Report Explained: Growth, Risks, and Legal Drama
Buy Hold Rant - Stocks and InvestingMar 15, 2026
Hims & Hers Health reported earnings, beating EPS estimates but slightly missing revenue. The company, perceived as a marketing firm selling white-labeled generics, faces legal challenges from Novo Nordisk over a GLP-1 pill. Despite its popularity, the creator expresses concerns about Hims' business model, prescription process, and premium pricing, leading to a decision to avoid the stock.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.